Narmac, 

I've talked about Jardiance/empagliflozin and other SGLT2 inhibs on here a bunch before. 14% RRR in 3-point MACE in EMPA-REG Outcomes trial from 2015, primarily driven by 38% reduction in cardiovascular death but no significant difference for individual events of non-fatal myocardial infarction or non-fatal stroke. Also achieved 32% reduction in all cause mortality and 35% reduction in hospitalization for heart failure. Another SGLT2 inhibitor Canagliflozin/Invokana in CANVAS trial also achieved 14% RRR in 3-point MACE but no one individual component was significantly reduced. Most recently a third SGLT2 inhibitor Dopagliflozin/Farxiga met its primary endpoint in DECLARE-TIMI and full results will be at American Heart Association next month.

Plus, the SGLT2 inhibs increase the risk of flesh eating genital infections for an added bonus.

The grand slam for BETonMACE will be a great 3-point MACE RRR, significant reductions in all 3 individual 3-point MACE components, and a huge reduction in cardiovascular death.

BearDownAZ